Scott Power

I thought I'd look at a couple of the emerging healthcare names with near-term catalysts, specifically some quarterly sales that are going to be reported in January. They're not formally covered, but Derek Jellinek and I have had the opportunity to meet with management over the last month, and we've... Show More

Scott Power

The healthcare sector has been very strong this year, and here we touch on eight players within it. There have also been a couple of laggards in that space too, and they are the IVF players. So we've been sitting with neutral recommendations on the space the last two years.... Show More

Scott Power

Mayne Pharma has come under a fair bit of selling pressure following further investigations into price fixing for some of their generic drugs. The company reported that impact on their earnings would be minimal and the share price recovered a little bit on the back of that, but at one... Show More

Scott Power

Sirtex is still trading 33% below its level prior to last week’s trading update. Issues such as competition, reimbursement, complex work-up, short sales cycle, and the first admission that SIRFLOX survival data is needed to drive front-line use were cited as causes for the weakness. While these issues are nothing... Show More

Scott Power

Increased 1Q variability in Hospital volumes/case mix has seen HSO warn of soft divisional revenue growth and flat divisional growth if the trend continues through FY17. Negative publicity around affordability and consumer confidence were cited as the main cause of weakness, with October looking likely to improve and no fundamental... Show More

Scott Power

The Australian dollar (AUD) has rallied c7% against the US dollar since the start of 2016 on a combination of uncertainty about global growth and US Federal Reserve’s about-face on targeted interest rate rises amid lower growth and inflation, helping to support the currencies of commodity-exporting nations such as Australia.... Show More

Scott Power

Blackmores results are in, and it’s a huge jump in profit, up 160% to $48m. Despite the strong result, the shares were sold off slightly as the market was expecting the profit surge. The result couldn’t be faulted, with sales up 65%. Sales directly to China have been strong, now... Show More

Scott Power

Sonic 1H16 results were in line with our expectations, with solid underlying earnings growth driven by ex-Australia ops, somewhat overcoming well-flagged government policies that negatively impacted domestic businesses. Importantly, strong organic laboratory growth, profit enhancements across the domestic front, and gains from recent acquisitions and FX tailwinds, reiterate the outlook... Show More

Scott Power

CSL hosted its annual R&D day yesterday. Overall, we came away with a better appreciation of the company’s protein therapeutics technical platform, underpinned by a core focus on plasma fractionation and recombinant technology across four key verticals (ie Immunoglobulins (43% of total sales), Specially Products (17% of total sales), Haemophilia... Show More

Scott Power

“The Morgans Healthcare team has today released its top 5 emerging healthcare names with some near term milestones. Companies that we’re looking at that we think over the next 1-2 months will produce some catalysts that if positive will drive the share prices.” For the list of 5 stocks and... Show More

Scott Power

Resmed 1QFY15 underlying earnings were in line with expectations, with another quarter of double-digit sales growth, underpinned by strong US flow generator uptake and continued strength in masks beating market growth rates. While ROW sales continue to be impacted by disappointing SERVE-HF trial results, the impact remains ring-fenced and failed... Show More

Scott Power

Investing in small/micro-cap healthcare is challenging due to a lengthy and binary driven product cycle, which is punctuated with bouts of excessive share volatility. While a pure momentum strategy that rides on investor enthusiasm, knowledge of the timing and share impact of different catalysts (eg regulatory events, clinical trial readouts,... Show More

Scott Power

TPG and The Carlyle Group have sold A$810m, or 53% of their A$1.8bn stake in HSO (will retain a 17.8% holding). Our Investment view is the company has a solid track record of strong earnings growth of 13% over the last 4 years, along with stable, high CF generation and... Show More

No comments.